Search hospitals > Illinois > Glenview
Northwestern Medicine Glenview Outpatient Center
Claim this profileGlenview, Illinois 60026
Global Leader in Cancer
Conducts research for Breast Cancer
Conducts research for Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Serous Cystadenocarcinoma
11 reported clinical trials
18 medical researchers
Summary
Northwestern Medicine Glenview Outpatient Center is a medical facility located in Glenview, Illinois. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Serous Cystadenocarcinoma and other specialties. Northwestern Medicine Glenview Outpatient Center is involved with conducting 11 clinical trials across 67 conditions. There are 18 research doctors associated with this hospital, such as Aparna Kalyan, Sunandana Chandra, Devalingam Mahalingam, MBBChBAO, and Jochen H. Lorch, M.D..Area of expertise
1Cancer
Global LeaderStage IV
Stage III
HER2 positive
2Breast Cancer
ER positive
HER2 positive
PR positive
Top PIs
Aparna KalyanNorthwestern University1 year of reported clinical research
Expert in Cancer
Studies Bile Duct Cancer
20 reported clinical trials
39 drugs studied
Sunandana ChandraNorthwestern University1 year of reported clinical research
Expert in Melanoma
Expert in Skin Cancer
22 reported clinical trials
31 drugs studied
Devalingam Mahalingam, MBBChBAONorthwestern University5 years of reported clinical research
Studies Solid Tumors
Studies Tumors
18 reported clinical trials
54 drugs studied
Jochen H. Lorch, M.D.Northwestern University4 years of reported clinical research
Studies Cancer
Studies Squamous Cell Carcinoma
15 reported clinical trials
25 drugs studied
Clinical Trials running at Northwestern Medicine Glenview Outpatient Center
Breast Cancer
Cancer
Diffuse Large B-Cell Lymphoma
Lung Cancer
Ovarian Cancer
Liposarcoma
Soft Tissue Sarcoma
Fallopian Tube Cancer
Rectal Cancer
Nasopharyngeal Carcinoma
Chemotherapy + Hormone Therapy
for Breast Cancer
This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
Durvalumab + Chemotherapy
for Breast Cancer
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint Ultrahigh (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint Ultrahigh Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria
Pembrolizumab
for Triple-Negative Breast Cancer
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Northwestern Medicine Glenview Outpatient Center?
Northwestern Medicine Glenview Outpatient Center is a medical facility located in Glenview, Illinois. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Serous Cystadenocarcinoma and other specialties. Northwestern Medicine Glenview Outpatient Center is involved with conducting 11 clinical trials across 67 conditions. There are 18 research doctors associated with this hospital, such as Aparna Kalyan, Sunandana Chandra, Devalingam Mahalingam, MBBChBAO, and Jochen H. Lorch, M.D..